Supplemental Figure S1



Supplemental Figure S1. *N*-myristoylation status of Vac8 mutants assessed by mobility shift. Vac8-myc WT and cysteine mutants were partially purified from *E. coli* coexpressing Nmt1 as described in Experimental Procedures. The proteins were resolved on a 7.5% acrylamide gel with 4 M urea and analyzed by anti-myc immunoblot. Non-myristoylated and *N*-myristoylated standards were prepared from soluble lystates of *E. coli* expressing Vac8-myc in the absence or presence of Nmt1. The partially purified proteins have a similar mobility to that of the myristoylated standard suggesting that the Vac8-myc WT and cysteine mutant preparations are fully myristoylated. Supplemental Figure S2



Supplemental Figure S2. *N*-myristoylation of substrates in *E. coli*. (A) *E. coli* BL21(DE3) were transformed with pML1164 (*PSR2-MYC-6xHIS*), pML1164 and pBB131 (*NMT1*), or pML658 (*VAC8-MYC*) and pBB131. Cultures (50 ml) were grown to  $OD_{600} = 0.4$  and induced with 0.3 mM IPTG in the presence of 1 µg/ml chloramphenicol for 60 min at 30°C. Each culture (1 ml) was incubated with 1.2 nmol (50 µCi) [<sup>3</sup>H]myristic acid for 4 h at 30°C. Cells were collected, suspended in 100 µl lysis buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 1 mM DTT, 2 mg/ml lysozyme, 1x PTT), incubated on ice for 30 min and fractionated at 200,000g for 20 min. The soluble fraction was collected and equal volumes from each condition were separated by SDS-PAGE and prepared for fluorography. Vac8-myc, but not Psr2-myc-6xHis, was radiolabeled with [<sup>3</sup>H]myristate. Psr2-myc-6xHis is present in lanes 1 and 2, and Vac8-myc is present in lane 3 as shown by anti-myc immunoblot. (B) Ygl108 and Meh1 were analyzed for N-myristoylation as described in A. Both incorporated [<sup>3</sup>H]myristate when coexpressed with Nmt1 in *E. coli*. (C) Vac8[SH4], Vac8[SH4](C $\Delta$ ), Meh1[SH4], and Meh1[SH4](C $\Delta$ ) were analyzed for N-myristoylation as described in A. All incorporated [<sup>3</sup>H]myristate when coexpressed with Nmt1 in *E. coli*.

Supplemental Figure S3

A

0.25	0.25 Pfa3	0.25 Akr1	0.5 -	0.5 Pfa3	0.5 Akr1	1.	0	1.0 Pfa3	1.0 Akr1	2.0	2.0 Pfa3	2.0 Akr1	Substrate ( $\mu M$ )	
	-			-	-		•	-			-		Vac8	(8 hours)
		-			-			Sec. 1	1	<b>A</b> rcald	-	-	Meh1	(2 days)
		-		-	-			-	-	dependent		-	Vac8[SH4]-GFP	(8 hours)
	-	and some		-	-	day so the		-	-	-	-	-	Meh1[SH4]-GFP	(2 days)
		Marcall		Second	Manada			-	-		-	-	Vac8[SH4]-Meh1	(8 hours)

## B

Competitor (µM): 0 0.1 0.25 0.5 1.0 2.0



## С

Competitor (µM): 0 0.1 0.25 0.5 1.0 2.0



Supplemental Figure S3. (A) **Representative fluorograph from data in Figure 4 and 5b**. Increasing amounts of myr-Vac8, myr-Meh1, myr-Vac8[SH4]-GFP, myr-Meh1[SH4]-GFP, myr-Vac8[SH4]-Meh1, or myr-Meh1[SH4]-Vac8 were incubated with [<sup>3</sup>H]Palm-CoA and either no enzyme, 10 nM Pfa3-Flag, or 10 nM Akr1-Flag. Reactions were processed for fluorograph and exposed to film for the time indicated to the right of each panel. (B) **Representative fluorograph from data in Figure 6a**. Increasing amounts of myr-Vac8(C $\Delta$ ), myr-Vac8[SH4]-GFP, myr-Vac8[SH4](C $\Delta$ )-GFP, or myr-G $\alpha_{i1}$  were incubated with 0.1  $\mu$ M myr-Vac8, [<sup>3</sup>H]Palm-CoA, and partially purified Pfa3-6xHis-Flag. Reactions were processed for fluorograph from data in Figure 6b. Increasing amounts of myr-Vac8(C $\Delta$ ), myr-Vac8[SH4](C $\Delta$ )-GFP, myr-Vac8[Arm1-11](C $\Delta$ ), myr-Vac8[Arm1-10](C $\Delta$ ), or myr-Vac8[Arm $\Delta$ 11](C $\Delta$  were incubated with 0.1  $\mu$ M myr-Vac8, [<sup>3</sup>H]Palm-CoA, and partially purified Pfa3-6xHis-GFP, myr-Vac8, [<sup>3</sup>H]Palm-CoA, and partially (C $\Delta$ )-GFP, myr-Vac8[Arm1-11](C $\Delta$ ), myr-Vac8[Arm1-10](C $\Delta$ ), or myr-Vac8[Arm $\Delta$ 11](C $\Delta$  were incubated with 0.1  $\mu$ M myr-Vac8, [<sup>3</sup>H]Palm-CoA, and partially purified Pfa3-6xHis-Flag. Reactions were processed for fluorograph and exposed to film for 4 h.

Figure 4 - Substrate	Expt	<b>Arbitrary Units</b>
A. Myr-Vac8	1	3008
	2	3430
	3	6311
B. Myr-Vac8[SH4]-GFP	1	32072
-	2	25512
	3	38416
C. Myr-Meh1	1	14036
-	2	10444
	3	9660
<b>D.</b> Myr-Meh1[SH4]-GFP	1	4708
	2	8916
	3	4876
Figure 5 - Substrate	Expt	<b>Arbitrary Units</b>
B. Myr-Meh1[SH4]-Vac8	1	4932
	2	3991
	3	2667

STable I. 100% values for densitometry in Figure 4 & 5B

Stable II. 100% values for densit	ometry m	Figure oA.
Competitor	Expt	<b>Arbitrary Units</b>
Myr-Vac8(C $\Delta$ ) ( $\bullet$ )	1	1791
	2	4198
	3	6374
Myr-Vac8[SH4]-GFP (▲)	1	1291
	2	3894
	3	6093
Myr-Vac8[SH4](CΔ)-GFP (■)	1	2183
	2	4352
	3	6480
Myr -G $\alpha_{i1}$ ( $\blacklozenge$ )	1	2797
•	2	3911
	3	5863

STable II. 100% values for densitometry in Figure 6A.

STable III. 100% values for densitometry in Figure 6B.

Competitor	Expt	Arbitrary Units
$Mvr-Vac8(CA)(\bullet)$	1	3674
	2	1913
	3	4849
Mvr-Vac8[SH4](CΔ)-GFP (■)	1	3880
	2	2107
	3	4949
Myr-Vac8[Arm1-11](C $\Delta$ ) ( $\Delta$ )	1	3815
	2	2068
	3	4497
Myr-Vac8[Arm1-10](C $\Delta$ ) ( $\diamondsuit$ )	1	4002
	2	1956
	3	4775
MyrVac8[Arm $\Delta$ 11](C $\Delta$ ) ( $\Box$ )	1	3870
	2	1966
	3	4830